Ram Prasad Sahu
Ram Prasad Sahu
Page 96 - Ram Prasad Sahu/undefined
Will M&M's smooth UV ride continue?
New launches and aggressive competitors could dent the sales growth trajectory for the king of the utility vehicles segment
Maruti Suzuki: Regaining share, margins
Better-than-industry volume growth, revival in export sales and favourable product mix should help get back lost market share
Analysis: Maruti Suzuk re-gaining share, margins
Better than industry volume growth in domestic market, revival in export sales coupled with favourable product mix should help Maruti get back lost market share and improve margins
Bharti Infratel: High valuations limit gains
The company is on a strong wicket in cash flows, but its IPO valuations are quite high
Analysis: Fortis HealthCare moving in the right direction
The deal to sell its Australian assets will help pare debt, while its focus on Asian business especially India coupled with an asset light model will help drive growth
Container Corp: Lower port traffic, domestic volumes impact performance
Contrainer traffic up barely 2% in first 5 months on poor performance of cos which account for 70% of overall container traffic
Poor outlook hits Bharat Forges prospects
Inventory correction and fall in orders likely to impact the company's exports going ahead
Ashok Leyland to maintain margins at 10%
The company posted a 210 bps sequential jump in margins to 10.1%
RCom Q2 net plunges 60% to Rs 102 cr
As the mobile phone carrier struggled with its heavy debt load
Playing the waiting game
Falling competitive intensity and increase in data usage should benefit Bharti Airtel
Bharti Airtel: Playing the waiting game
Falling competitive intensity and increase in data usage should benefit the company
Divi's Labs: Healthy show despite cost hurdles
Even as power costs are likely to remain elevated, higher operating leverage at its new SEZ should result in better margins in FY13
Ashok Leyland gaining ground
After a good September quarter and a recovery expected in FY14, analysts are bullish on prospects of the company
Wockhardt: More gains in the offing
Growth will be driven by its performance in the US (48% of overall sales) where the company plans to launch 10 products every year.
More gains in the offing for Wockhardt
5% rise in stock price since Q2 results to touch 52-week high of Rs 1,784
Pharma review: Good quarter, healthy prospects
Most major pharma companies turned out a strong performance in the quarter with results better than expectations.
Pharma: Good quarter, healthy prospects
Major firms reported 30% revenue growth for the quarter ended September
